| dc.contributor.author | Garrett, Nigel | |
| dc.contributor.author | Tapley, Asa | |
| dc.contributor.author | Hudson, Aaron | |
| dc.contributor.author | Et al. | |
| dc.date.accessioned | 2025-02-17T07:29:52Z | |
| dc.date.available | 2025-02-17T07:29:52Z | |
| dc.date.issued | 2025-02-01 | |
| dc.identifier.uri | https://repository.maseno.ac.ke/handle/123456789/6310 | |
| dc.description | https://doi.org/10.1016/j.eclinm.2024.
103054 | en_US |
| dc.description.abstract | With limited access to mRNA COVID-19 vaccines in lower income countries, and people living with HIV (PLWH) largely excluded from clinical trials, Part A of the multicentre CoVPN 3008 (Ubuntu) study aimed to assess the safety of mRNA-1273, the relative effectiveness of hybrid versus vaccine immunity, and SARS-CoV-2 viral persistence among PLWH in East and Southern Africa during the omicron outbreak. | en_US |
| dc.description.sponsorship | National Institute of Allergy and Infectious Diseases. | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | People living with HIV; SARS-CoV-2; mRNA-1273; Hybrid immunity; Vaccine immunity; COVID-19 | en_US |
| dc.title | Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study | en_US |
| dc.type | Article | en_US |
